COMPANY

GT Medical Technologies

FDA-cleared device company Clinical Phase 3

Keywords: oncology tumors Glioblastoma Recurrent Brain Tumor Brain Tumor Primary Brain Tumor Brain Tumor - Metastatic Adult: Glioblastoma Brain Tumor Adult Meningioma Brain Tumor Brain Metastases GammaTile

Location: Tempe, AZ · source · Oct 15, 2026

Profile checked Oct 10, 2026

5Trials (company is sponsor)

Funding and NIH signals

SEC Form D raise Raised $50.06M (Form D filed Jul 22, 2026). SEC Form D 0001723008-26-000002 (Jul 22, 2026)
Evidence (1 event)
- Jul 22, 2026 · SEC Form D 0001723008-26-000002
  Name of Issuer: GT MEDICAL TECHNOLOGIES, INC.; CIK: 1723008; Address: Tempe, AZ; Submission type: D; Filing date: 2026-07-22; Industry Group: Other Health Care; Date of First Sale: 2026-05-08; Types of Securities Offered: Equity, Option/warrant, Security to be acquired; Business combination transaction: false; Total Offering Amount: 100056698; Total Amount Sold: 50056676; Federal exemptions: 06b

Job counts as of Oct 18, 2026. All funding and NIH signals

Timeline

Dec 10, 2025 Trial start Phase 3: Beginning Radiation Immediately With GammaTile at GBM Excision Versus Standard of Care source ↗
2025-05 Trial start Phase 4: Post-operative Adjuvant Therapy w/wo GammaTile + Systemic Therapy source ↗
Aug 17, 2022 Trial start Phase 4: GammaTile and Stupp in Newly Diagnosed GBM source ↗
Apr 6, 2021 Trial start Phase 3: Post-Surgical Stereotactic Radiotherapy (SRT) Versus GammaTile-ROADS (Radiation One and Done Study) source ↗
Sep 11, 2020 Trial start —: Registry of Patients With Brain Tumors Treated With STaRT (GammaTiles) source ↗

Upcoming milestones

Dec 1, 2027 (ESTIMATED) · Phase 4 · GammaTile and Stupp in Newly Diagnosed GBM · NCT05342883
Oct 31, 2028 (ESTIMATED) · · Registry of Patients With Brain Tumors Treated With STaRT (GammaTiles) · NCT04427384
Aug 30, 2029 (ESTIMATED) · Phase 3 · Post-Surgical Stereotactic Radiotherapy (SRT) Versus GammaTile-ROADS (Radiation One and Done Study) · NCT04365374
2031-12 (ESTIMATED) · Phase 3 · Beginning Radiation Immediately With GammaTile at GBM Excision Versus Standard of Care · NCT07195591

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 5

Record	Title	Phase	Status	Start	Primary completion
NCT07195591	Beginning Radiation Immediately With GammaTile at GBM Excision Versus Standard of Care	Phase 3	Recruiting	Dec 10, 2025	2031-12 (estimated)
NCT04427384	Registry of Patients With Brain Tumors Treated With STaRT (GammaTiles)	Not listed	Recruiting	Sep 11, 2020	Oct 31, 2028 (estimated)
NCT04365374	Post-Surgical Stereotactic Radiotherapy (SRT) Versus GammaTile-ROADS (Radiation One and Done Study)	Phase 3	Active, not recruiting	Apr 6, 2021	Aug 30, 2029 (estimated)
NCT05342883	GammaTile and Stupp in Newly Diagnosed GBM	Phase 4	Active, not recruiting	Aug 17, 2022	Dec 1, 2027 (estimated)
NCT05900908	Post-operative Adjuvant Therapy w/wo GammaTile + Systemic Therapy	Phase 4	Withdrawn	2025-05	2026-06 (estimated)